Dr. Anahit A. Zeynalyan, MD
Rheumatology (Rheumatology Physician)
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2019
Licensed in Texas since 2024, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2019Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
TX license U9398 (first issued 2024; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Rheumatology Associates and Subsidiary (23 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Humira(Cf) Pen (adalimumab) Other prescribers in Dallas, TX | 50 |
| Enbrel Sureclick (etanercept) Other prescribers in Dallas, TX | 46 |
| Sulfasalazine Other prescribers in Dallas, TX | 45 |
| Methotrexate (methotrexate sodium) Other prescribers in Dallas, TX | 40 |
| Prednisone Other prescribers in Dallas, TX | 38 |
| Leflunomide Other prescribers in Dallas, TX | 33 |
| Actemra Actpen (tocilizumab) | 31 |
| Humira Pen (adalimumab) Other prescribers in Dallas, TX | 25 |
| Folic Acid Other prescribers in Dallas, TX | 25 |
| Hydroxychloroquine Sulfate Other prescribers in Dallas, TX | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 53 payments worth $1,013 in total to this clinician.
| AbbVie Inc. | $316 |
|---|---|
| Novartis Pharmaceuticals Corporation | $225 |
| Amgen Inc. | $140 |
| UCB, Inc. | $124 |
| E.r. Squibb & Sons, L.l.c. | $76.31 |
| GlaxoSmithKline, LLC. | $40.70 |
| Genentech USA, Inc. | $32.95 |
| Janssen Biotech, Inc. | $30.05 |
| Food and Beverage | $1,013 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.